Common and distinct patterns of acquired uniparental disomy and homozygous deletions between lung squamous cell carcinomas and lung adenocarcinoma
Neoplasia. 2023 Oct 4;45:100932. doi: 10.1016/j.neo.2023.100932. Online ahead of print.ABSTRACTAcquired uniparental disomy (aUPD) is a chromosomal alteration that can lead to homozygosity of existing aberrations. We used data from The Cancer Genome Atlas SNP-based arrays to identify distinct and common aUPD profiles in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). Moreover, we tested relevance of aUPD for homozygous deletion (HMD), overall survival (OS), and recurrence-free survival (RFS). Overall, we found significantly higher aUPD (q = 5.34E-09) in LUSC than in LUAD. A significant portion of HMD was...
Source: Neoplasia - October 6, 2023 Category: Cancer & Oncology Authors: Musaffe Tuna Gordon B Mills Christopher I Amos Source Type: research
Retraction notice to "Inhibition of HDACs reduces Ewing sarcoma tumor growth through EWS-FLI1 protein destabilization" [Neoplasia 27 (2022) 100784]
Neoplasia. 2023 Oct;44:100916. doi: 10.1016/j.neo.2023.100916. Epub 2023 Jul 12.NO ABSTRACTPMID:37802556 | DOI:10.1016/j.neo.2023.100916 (Source: Neoplasia)
Source: Neoplasia - October 6, 2023 Category: Cancer & Oncology Authors: Gloria Pedot Joana Gra ça Marques Philip P Amb ühl Marco Wachtel Stephanie Kasper Quy A Ngo Felix K Niggli Beat W Sch äfer Source Type: research
Retraction notice to Corrigendum to "Inhibition of HDACs reduces Ewing sarcoma tumor growth through EWS-FLI1 protein destabilization" [Neoplasia 31 (2022) 100805]
Neoplasia. 2023 Oct;44:100917. doi: 10.1016/j.neo.2023.100917. Epub 2023 Jul 8.NO ABSTRACTPMID:37802557 | DOI:10.1016/j.neo.2023.100917 (Source: Neoplasia)
Source: Neoplasia - October 6, 2023 Category: Cancer & Oncology Authors: Gloria Pedot Joana Gra ça Marques Philip P Amb ühl Marco Wachtel Stephanie Kasper Quy A Ngo Felix K Niggli Beat W Sch äfer Source Type: research
Common and distinct patterns of acquired uniparental disomy and homozygous deletions between lung squamous cell carcinomas and lung adenocarcinoma
Neoplasia. 2023 Oct 4;45:100932. doi: 10.1016/j.neo.2023.100932. Online ahead of print.ABSTRACTAcquired uniparental disomy (aUPD) is a chromosomal alteration that can lead to homozygosity of existing aberrations. We used data from The Cancer Genome Atlas SNP-based arrays to identify distinct and common aUPD profiles in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). Moreover, we tested relevance of aUPD for homozygous deletion (HMD), overall survival (OS), and recurrence-free survival (RFS). Overall, we found significantly higher aUPD (q = 5.34E-09) in LUSC than in LUAD. A significant portion of HMD was...
Source: Neoplasia - October 6, 2023 Category: Cancer & Oncology Authors: Musaffe Tuna Gordon B Mills Christopher I Amos Source Type: research
Retraction notice to "Inhibition of HDACs reduces Ewing sarcoma tumor growth through EWS-FLI1 protein destabilization" [Neoplasia 27 (2022) 100784]
Neoplasia. 2023 Oct;44:100916. doi: 10.1016/j.neo.2023.100916. Epub 2023 Jul 12.NO ABSTRACTPMID:37802556 | DOI:10.1016/j.neo.2023.100916 (Source: Neoplasia)
Source: Neoplasia - October 6, 2023 Category: Cancer & Oncology Authors: Gloria Pedot Joana Gra ça Marques Philip P Amb ühl Marco Wachtel Stephanie Kasper Quy A Ngo Felix K Niggli Beat W Sch äfer Source Type: research
Retraction notice to Corrigendum to "Inhibition of HDACs reduces Ewing sarcoma tumor growth through EWS-FLI1 protein destabilization" [Neoplasia 31 (2022) 100805]
Neoplasia. 2023 Oct;44:100917. doi: 10.1016/j.neo.2023.100917. Epub 2023 Jul 8.NO ABSTRACTPMID:37802557 | DOI:10.1016/j.neo.2023.100917 (Source: Neoplasia)
Source: Neoplasia - October 6, 2023 Category: Cancer & Oncology Authors: Gloria Pedot Joana Gra ça Marques Philip P Amb ühl Marco Wachtel Stephanie Kasper Quy A Ngo Felix K Niggli Beat W Sch äfer Source Type: research
ΔNp63 silencing, DNA methylation shifts, and epithelial-mesenchymal transition resulted from TAp63 genome editing in squamous cell carcinoma
Neoplasia. 2023 Sep 29;45:100938. doi: 10.1016/j.neo.2023.100938. Online ahead of print.ABSTRACTTP63 (p63) is strongly expressed in lower-grade carcinomas of the head and neck, skin, breast, and urothelium to maintain a well-differentiated phenotype. TP63 has two transcription start sites at exons 1 and 3' that produce TAp63 and ΔNp63 isoforms, respectively. The major protein, ΔNp63α, epigenetically activates genes essential for epidermal/craniofacial differentiation, including ΔNp63 itself. To examine the specific role of weakly expressed TAp63, we disrupted exon 1 using CRISPR-Cas9 homology-directed repair in a head ...
Source: Neoplasia - October 1, 2023 Category: Cancer & Oncology Authors: Iyoko Katoh Keiichi Tsukinoki Ryu-Ichiro Hata Shun-Ichi Kurata Source Type: research
ΔNp63 silencing, DNA methylation shifts, and epithelial-mesenchymal transition resulted from TAp63 genome editing in squamous cell carcinoma
Neoplasia. 2023 Sep 29;45:100938. doi: 10.1016/j.neo.2023.100938. Online ahead of print.ABSTRACTTP63 (p63) is strongly expressed in lower-grade carcinomas of the head and neck, skin, breast, and urothelium to maintain a well-differentiated phenotype. TP63 has two transcription start sites at exons 1 and 3' that produce TAp63 and ΔNp63 isoforms, respectively. The major protein, ΔNp63α, epigenetically activates genes essential for epidermal/craniofacial differentiation, including ΔNp63 itself. To examine the specific role of weakly expressed TAp63, we disrupted exon 1 using CRISPR-Cas9 homology-directed repair in a head ...
Source: Neoplasia - October 1, 2023 Category: Cancer & Oncology Authors: Iyoko Katoh Keiichi Tsukinoki Ryu-Ichiro Hata Shun-Ichi Kurata Source Type: research
ΔNp63 silencing, DNA methylation shifts, and epithelial-mesenchymal transition resulted from TAp63 genome editing in squamous cell carcinoma
Neoplasia. 2023 Sep 29;45:100938. doi: 10.1016/j.neo.2023.100938. Online ahead of print.ABSTRACTTP63 (p63) is strongly expressed in lower-grade carcinomas of the head and neck, skin, breast, and urothelium to maintain a well-differentiated phenotype. TP63 has two transcription start sites at exons 1 and 3' that produce TAp63 and ΔNp63 isoforms, respectively. The major protein, ΔNp63α, epigenetically activates genes essential for epidermal/craniofacial differentiation, including ΔNp63 itself. To examine the specific role of weakly expressed TAp63, we disrupted exon 1 using CRISPR-Cas9 homology-directed repair in a head ...
Source: Neoplasia - October 1, 2023 Category: Cancer & Oncology Authors: Iyoko Katoh Keiichi Tsukinoki Ryu-Ichiro Hata Shun-Ichi Kurata Source Type: research
ΔNp63 silencing, DNA methylation shifts, and epithelial-mesenchymal transition resulted from TAp63 genome editing in squamous cell carcinoma
Neoplasia. 2023 Sep 29;45:100938. doi: 10.1016/j.neo.2023.100938. Online ahead of print.ABSTRACTTP63 (p63) is strongly expressed in lower-grade carcinomas of the head and neck, skin, breast, and urothelium to maintain a well-differentiated phenotype. TP63 has two transcription start sites at exons 1 and 3' that produce TAp63 and ΔNp63 isoforms, respectively. The major protein, ΔNp63α, epigenetically activates genes essential for epidermal/craniofacial differentiation, including ΔNp63 itself. To examine the specific role of weakly expressed TAp63, we disrupted exon 1 using CRISPR-Cas9 homology-directed repair in a head ...
Source: Neoplasia - October 1, 2023 Category: Cancer & Oncology Authors: Iyoko Katoh Keiichi Tsukinoki Ryu-Ichiro Hata Shun-Ichi Kurata Source Type: research
DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study
Neoplasia. 2023 Sep 26;45:100937. doi: 10.1016/j.neo.2023.100937. Online ahead of print.ABSTRACTThe therapeutic scenario of Human Epidermal Growth Factor Receptor 2 positive advanced breast cancer (ABC) has been recently enriched by a number of innovative agents, which are reshaping treatment sequence. While randomized trials have documented an advantage in terms of efficacy, for the newly available agents we lack effectiveness and tolerability evidence from the real-world setting. Similarly, the identification of predictive biomarkers might improve clinical decision. We herein describe the outline of a prospective/retrosp...
Source: Neoplasia - September 28, 2023 Category: Cancer & Oncology Authors: Giulia Bon Eriseld Krasniqi Manuela Porru Lorenzo D'Ambrosio Stefano Scalera Marcello Maugeri-Sacc à Francesca Sofia Di Lisa Lorena Filomeno Teresa Arcuri Andrea Botticelli Daniele Santini Maria Agnese Fabbri Giuliana D'Auria Claudio Pulito Giovanni Blan Source Type: research
ABBV-744 induces autophagy in gastric cancer cells by regulating PI3K/AKT/mTOR/p70S6k and MAPK signaling pathways
In this study, we evaluated the effect of ABBV-744 on gastric cancer cells and explored the possible underlying mechanisms. We found that ABBV-744 inhibited the growth of gastric cancer cells and patient-derived tumor organoids in a dose-dependent manner. Cellular experiments revealed that ABBV-744 induced mitochondria damage, reactive oxygen species accumulation, cell cycle arrest and apoptotic cell death in gastric cancer cells. Transcriptomic analysis using RNA-sequencing data identified autophagy as a crucial pathway involved in the cell death caused by ABBV-744. Mechanically, further studies showed that ABBV-744 induc...
Source: Neoplasia - September 28, 2023 Category: Cancer & Oncology Authors: Kun Wang Jiatong Tang Shengxian Fan Haochen Su Ranran Yu Yixuan Zhang Hao Wu Ying Lv Shu Zhang Xiaoping Zou Source Type: research
DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study
Neoplasia. 2023 Sep 26;45:100937. doi: 10.1016/j.neo.2023.100937. Online ahead of print.ABSTRACTThe therapeutic scenario of Human Epidermal Growth Factor Receptor 2 positive advanced breast cancer (ABC) has been recently enriched by a number of innovative agents, which are reshaping treatment sequence. While randomized trials have documented an advantage in terms of efficacy, for the newly available agents we lack effectiveness and tolerability evidence from the real-world setting. Similarly, the identification of predictive biomarkers might improve clinical decision. We herein describe the outline of a prospective/retrosp...
Source: Neoplasia - September 28, 2023 Category: Cancer & Oncology Authors: Giulia Bon Eriseld Krasniqi Manuela Porru Lorenzo D'Ambrosio Stefano Scalera Marcello Maugeri-Sacc à Francesca Sofia Di Lisa Lorena Filomeno Teresa Arcuri Andrea Botticelli Daniele Santini Maria Agnese Fabbri Giuliana D'Auria Claudio Pulito Giovanni Blan Source Type: research
ABBV-744 induces autophagy in gastric cancer cells by regulating PI3K/AKT/mTOR/p70S6k and MAPK signaling pathways
In this study, we evaluated the effect of ABBV-744 on gastric cancer cells and explored the possible underlying mechanisms. We found that ABBV-744 inhibited the growth of gastric cancer cells and patient-derived tumor organoids in a dose-dependent manner. Cellular experiments revealed that ABBV-744 induced mitochondria damage, reactive oxygen species accumulation, cell cycle arrest and apoptotic cell death in gastric cancer cells. Transcriptomic analysis using RNA-sequencing data identified autophagy as a crucial pathway involved in the cell death caused by ABBV-744. Mechanically, further studies showed that ABBV-744 induc...
Source: Neoplasia - September 28, 2023 Category: Cancer & Oncology Authors: Kun Wang Jiatong Tang Shengxian Fan Haochen Su Ranran Yu Yixuan Zhang Hao Wu Ying Lv Shu Zhang Xiaoping Zou Source Type: research
DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study
Neoplasia. 2023 Sep 26;45:100937. doi: 10.1016/j.neo.2023.100937. Online ahead of print.ABSTRACTThe therapeutic scenario of Human Epidermal Growth Factor Receptor 2 positive advanced breast cancer (ABC) has been recently enriched by a number of innovative agents, which are reshaping treatment sequence. While randomized trials have documented an advantage in terms of efficacy, for the newly available agents we lack effectiveness and tolerability evidence from the real-world setting. Similarly, the identification of predictive biomarkers might improve clinical decision. We herein describe the outline of a prospective/retrosp...
Source: Neoplasia - September 28, 2023 Category: Cancer & Oncology Authors: Giulia Bon Eriseld Krasniqi Manuela Porru Lorenzo D'Ambrosio Stefano Scalera Marcello Maugeri-Sacc à Francesca Sofia Di Lisa Lorena Filomeno Teresa Arcuri Andrea Botticelli Daniele Santini Maria Agnese Fabbri Giuliana D'Auria Claudio Pulito Giovanni Blan Source Type: research
